Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease
- 15 October 1993
- journal article
- research article
- Published by Wiley in American Journal of Medical Genetics
- Vol. 48 (3), 166-168
- https://doi.org/10.1002/ajmg.1320480311
Abstract
Aberrant detoxification of environmental agents may be the basis for an inherited predisposition to Parkinson's disease. A CYP2D6 genetic marker of the debrisoquine hydroxylase “poor metabolizer” phenotype was found to be significantly increased in Parkinson's disease patients compared to controls, as has been shown in previous studies. Presence of this marker gives an odds ratio of 1.86 for Parkinson's disease (95% confidence interval 1.33–2.39, P < 0.02). For comparison, a CYP1A1 polymorphism, which is not known to be associated with aberrant drug metabolism, showed no association with Parkinson's disease in our study.Keywords
This publication has 9 references indexed in Scilit:
- Association of a monoamine oxidase B allele with Parkinson's diseaseAnnals of Neurology, 1993
- Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's diseaseThe Lancet, 1992
- Mutant debrisoquine hydroxylation genes in Parkinson's diseaseThe Lancet, 1992
- Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypesPharmacogenetics, 1991
- PCR detection of an A/G polymorphism within exon 7 of the CYP1A1 geneNucleic Acids Research, 1991
- Abnormal liver enzyme‐mediated metabolism in Parkinson's diseaseNeurology, 1991
- Association of Xba I allele (Xba I 44kb) of the human cytochrome P-450dbI (CYP2D6) gene in Japanese patients with idiopathic Parkinson’s diseasePublished by Springer Nature ,1991
- Identification of the primary gene defect at the cytochrome P450 CYP2D locusNature, 1990
- Evolution of the P450 gene superfamily:Trends in Genetics, 1990